Innovation, Liability, and Product Development: Key Takeaways from the Gilead Decision

On August 3, 2026, the California Supreme Court issued its decision in the Gilead Tenofovir Cases, rejecting a novel negligence theory that would have significantly expanded potential liability for pharmaceutical manufacturers. The ruling reverses a California Court of Appeal decision that had recognized what many have described as a "duty to innovate," a theory that would have permitted plaintiffs to pursue negligence claims based not on defects in an existing product, but rather on allegations that a manufacturer delayed bringing a safer alternative product to market.

Background

Berkley Life Sciences previously discussed the duty to innovate and the Gilead Tenofovir Cases in our 2024 review of life science litigation trends. 

The litigation arose from claims brought by approximately 24,000 individuals who alleged injuries from HIV medications containing tenofovir disoproxil fumarate (TDF). While plaintiffs acknowledged that the TDF-based medications were not defective, they alleged that the manufacturer, Gilead Sciences, delayed development and commercialization of an alternative compound, tenofovir alafenamide fumarate (TAF), which they contended provided similar efficacy with fewer side effects.

In other words, rather than challenging the safety or effectiveness of the approved TDF products themselves, plaintiffs argued that Gilead acted negligently by failing to accelerate development and commercialization of the allegedly safer alternative. The theory sought to impose liability based on research, development, and commercialization decisions rather than on a defect in the marketed product.

The Court's Analysis

Writing for the majority in a 6-1 decision, Justice Joshua Groban concluded that California products liability law has long tied a manufacturer's duty to the design, manufacture, and marketing of products free from defects. The court expressed concern that recognizing liability for delays in developing alternative products would untether negligence claims from the traditional requirement that plaintiffs demonstrate a defect in the product that caused their injury.

The court further noted that decisions regarding whether and when to develop a potential successor product involve complex scientific, regulatory, and business judgments. Determining whether a manufacturer acted reasonably in pursuing, delaying, or abandoning a development program would require courts and juries to second-guess decisions made under conditions of uncertainty and incomplete information.

The majority also highlighted the practical challenges of creating workable standards for evaluating such claims. Pharmaceutical development involves extensive clinical testing, regulatory review, resource allocation, and changing scientific understanding. The court found that imposing liability based on hypothetical alternative development timelines presented significant difficulties and lacked a clear limiting principle.

Innovation and Public Policy Considerations

A recurring and notable theme in the decision was the court's concern that a legal duty intended to encourage innovation could ultimately frustrate or discourage it. The court observed that imposing such a duty could influence how manufacturers prioritize and allocate resources across research programs. Manufacturers faced with potential liability for failing to pursue one development pathway over another may feel pressure to redirect resources from other potentially promising research programs. The court concluded that creating a new form of liability based on a manufacturer's innovation and product-development decisions could ultimately prove detrimental to public health and drug development.

Why the Decision Matters

The decision is important not only for pharmaceutical manufacturers but also for the broader life sciences sector and, more broadly, general product liability risk. 

At its core, the case presented a fundamental policy question: should courts evaluate the safety of products already on the market, or should they also evaluate the pace and direction of future innovation? The significance of that question extends beyond pharmaceuticals. Modern companies routinely make difficult decisions regarding the allocation of resources, investment, and development priorities, often under conditions of uncertainty and evolving regulatory and market expectations. The decision in Gilead may reflect a broader judicial reluctance to evaluate such complex decisions through the lens of hindsight, particularly where those decisions required balancing scientific, regulatory, and business priorities.

The issues raised in Gilead also did not arise in a vacuum. Courts have periodically been asked to expand liability beyond traditional product-defect theories, including through various forms of innovator liability. As we have previously discussed, cases like T.H. v. Novartis Pharmaceuticals Corp. explored whether liability could extend beyond the specific product used by the plaintiff and, in some cases, reach a different manufacturer. Gilead presented a variation on that broader theme. Rather than seeking to impose liability on a brand name manufacturer for injuries allegedly caused by the generic manufacturer's copied product, plaintiffs sought to impose liability on one manufacturer based on decisions it made concerning the development and commercialization of an entirely different product. In that respect, Gilead can be viewed as part of a continued effort by courts to define the boundaries of product liability law and determine when liability should, and should not, extend beyond the allegedly defective product itself.

Had the lower court's theory been allowed to stand, manufacturers could have faced claims challenging a wide range of research and development decisions, including product pipeline management, clinical trial prioritization, regulatory strategy, and commercialization timing. By rejecting the duty-to-innovate theory, the California Supreme Court reaffirmed the foundational principle of products liability law that liability is ordinarily predicated on proving a defect in the product that allegedly caused the injury. 

Although the case arose in the pharmaceutical context, the issues it raised may resonate across a broad range of life sciences and technology-driven industries. The ruling offers greater predictability for companies making difficult business decisions in highly regulated environments and for those tasked with evaluating product liability risk.

Looking Ahead

While the decision rejects this particular negligence theory under California law, product liability and failure-to-warn claims involving pharmaceutical products remain active areas of complex, high-stakes litigation across jurisdictions. Manufacturers continue to face scrutiny regarding product design, labeling, safety communications, and post-market surveillance activities.

Nevertheless, the Gilead decision represents a significant reaffirmation of established products liability principles that remain highly relevant in today's litigation environment. It also recognizes the unique scientific, regulatory, and public health considerations involved in pharmaceutical innovation. For life sciences companies, insurers, and risk professionals, the ruling provides important clarity regarding the boundaries of negligence liability and underscores the challenges of evaluating complex product-development decisions through the lens of retrospective litigation.

Authored by David Bryton, J.D., SVP & Chief Claims Officer

This post is for general informational purposes only and is not intended as legal or other professional advice.